Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of pelareorep in combination with Keytruda, Velcade and dexamethasone, to treat multiple myeloma

Trial Profile

A clinical trial of pelareorep in combination with Keytruda, Velcade and dexamethasone, to treat multiple myeloma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 31 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Pelareorep (Primary) ; Pembrolizumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2018 New trial record
    • 25 May 2018 According to an Oncolytics Biotech media release, this trial will be conducted at the USC Norris Comprehensive Cancer Center in collaboration with the Keck School of Medicine of University of Southern California (USC). This trial is an extension of the REO 019 study evaluating pelareorep in combination with Velcade and dexamethasone to treat multiple myeloma. The enrolment of the first patient is expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top